Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Incyte Corporation    INCY

Delayed Quote. Delayed  - 08/31 10:00:00 pm
81.1 USD   +0.15%
08/30 INCYTE : to Present at Upcoming Investor Conferences
08/29 INCYTE : Immunovaccine Announces Additional Positive Topline Results..
08/29 INCYTE : ranks 4th on Forbes list of Innovative companies
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
Latest news on INCYTE CORPORATION
08/30 INCYTE : to Present at Upcoming Investor Conferences
08/29 INCYTE : Immunovaccine Announces Additional Positive Topline Results from Phase ..
08/29 INCYTE : ranks 4th on Forbes list of Innovative companies
08/25 INCYTE : Forbes Magazine Names Incyte to its List of World’s Most Innovati..
08/24 NASDAQ 100 MOVERS : Intu, incy
08/23 NASDAQ 100 MOVERS : Myl, amat
08/22 NASDAQ 100 MOVERS : Viab, incy
08/12 MADRIGAL PHARMACEUTICALS : Richard S. Levy, M. D., Appointed to Madrigal Board o..
08/11 NASDAQ 100 MOVERS : Incy, yhoo
08/09 INCYTE : Management's Discussion and Analysis of Financial Condition and Results..
08/09 INCYTE : beats Street 2Q forecasts
08/09 INCYTE CORP : Results of Operations and Financial Condition, Financial Statement..
08/09 INCYTE : Reports 2016 Second-Quarter Financial Results and Updates Key Clinical ..
08/09 INCYTE : earnings, sales soar
08/08 NASDAQ 100 MOVERS : Nflx, qvca
08/04INCYTE CORPORATION : half-yearly earnings release
07/19 INCYTE CORP : Change in Directors or Principal Officers (form 8-K)
07/19 INCYTE : Updated Data for Epacadostat, Incyte’s Selective IDO1 Inhibitor, ..
07/15 NASDAQ 100 MOVERS : Nclh, incy
07/14 NASDAQ 100 MOVERS : Nxpi, csx
07/14 INCYTE : to Report Second Quarter Financial Results
07/06 NASDAQ 100 MOVERS : Aal, endp
07/01 INCYTE : Financial Statements and Exhibits (form 8-K/A)
06/30 INCYTE : FDA Grants Breakthrough Therapy Designation for Incyte's Ruxolitinib Ja..
06/30 INCYTE : Announces First Patient Treated in ECHO-301 Phase 3 Study
06/23 INCYTE : FDA Grants Breakthrough Therapy Designation for Incyte’s Ruxoliti..
06/22 INCYTE : Announces First Patient Treated in ECHO-301 Phase 3 Study
06/22 INCYTE : Phase I/II trial of INCAGN1876 in solid tumours starts
06/16 ELI LILLY : Baricitinib significantly reduces joint damage progression in rheuma..
06/11 INCYTE : study shows good response to treatment for some PV blood cancer patient..
06/10 INCYTE : New Phase 3 Data Show Jakafi® (ruxolitinib) is Superior to Best Availab..
06/09 INCYTE : and Moffitt Cancer Center Establish Multi-Year Oncology Research Allian..
06/09 INCYTE : Announces the Launch of the Incyte Charitable Giving Foundation
06/09 INCYTE : Baricitinib significantly reduces joint damage progression in rheumatoi..
06/09 INCYTE : Patient-reported outcomes across phase 3 studies of baricitinib demonst..
06/06 NASDAQ 100 MOVERS : Fast, wfm
06/06 INCYTE : Five-year Results from Phase 3 Study of Jakafi® (ruxolitinib) Show Sust..
06/02 INCYTE : forms charitable foundation to meet needs in Delaware
06/01 INCYTE CORP : Entry into a Material Definitive Agreement, Completion of Acquisit..
06/01 INCYTE : and Moffitt team up for blood cancer research programmes
06/01 INCYTE : and Moffitt Cancer Center Establish Multi-Year Oncology Research Allian..
05/31 INCYTE : Announces the Launch of the Incyte Charitable Giving Foundation
05/27 INCYTE CORP : Change in Directors or Principal Officers, Submission of Matters t..
05/19 ARIAD PHARMACEUTICALS : Reports First Quarter 2016 Financial Results and Progres..
05/19 INCYTE : Highlights Jakafi® (ruxolitinib) and Capmatinib Abstracts to be Present..
05/18 INCYTE : to Present at Upcoming Investor Conferences
05/10 ARIAD PHARMACEUTICALS : agrees to sell European operations to Incyte
05/10 NASDAQ 100 MOVERS : Nclh, amzn
05/10 Immunovaccine Announces Financial Results for Quarter Ended March 31, 2016
05/10 INCYTE : ARIAD Reports First Quarter 2016 Financial Results and Progress on Stra..
05/09 INCYTE : to acquire ARIAD’s European operations for $140m
05/09 INCYTE : buys ARIAD Pharma's European business for $140M; ARIAD up 5% premarket
05/09 INCYTE CORP : Results of Operations and Financial Condition, Financial Statement..
05/09 INCYTE : First Quarter Financial Results Conference Call and Webcast
05/09 INCYTE : misses 1Q profit forecasts
05/09 INCYTE : Reports 2016 First-Quarter Financial Results and Updates Shareholders o..
05/09 INCYTE : and ARIAD Announce Agreement for Incyte to Acquire ARIAD’s Europe..
05/04INCYTE CORPORATION : quaterly earnings release
04/28 INCYTE : Investor Event at AACR 2016 to Highlight Innovative and Diversified Res..
04/28 INCYTE : to Present at Upcoming Investor Conferences
04/18 INCYTE : Change in Directors or Principal Officers (form 8-K)
04/15 INCYTE : Investor Event at AACR 2016 to Highlight Innovative and Diversified Res..
04/15 INCYTE : Investor Event at AACR 2016 to Highlight Innovative and Diversified Res..
04/14 INCYTE : to Report First Quarter Financial Results
04/06 INCYTE : Entry into a Material Definitive Agreement (form 8-K)
04/06 Biotech Stocks Rally, Extending Recent Upward Trend
04/06 INCYTE : Acquires Rights from Lilly to Develop and Commercialize Ruxolitinib (Ja..
03/31 NASDAQ 100 MOVERS : Endp, incy
03/31 INCYTE : Phase 3 Study Findings Demonstrate Treatment with Baricitinib Results i..
03/29 Immunovaccine Announces 2015 Year-End Results
03/24 INCYTE : Immuno-oncology and Targeted Therapy Portfolio to be Featured at the AA..
03/24 NASDAQ 100 MOVERS : Pypl, incy
03/16 INCYTE : Immuno-oncology and Targeted Therapy Portfolio to be Featured at the AA..
03/09 NASDAQ 100 MOVERS : Regn, wdc
02/29 INCYTE : Joins Patient Organizations Worldwide in Recognition of Rare Disease Da..
1  2  3  4  5  6Next
Advertisement
Financials ($)
Sales 2016 1 047 M
EBIT 2016 76,5 M
Net income 2016 35,7 M
Finance 2016 43,4 M
Yield 2016 -
P/E ratio 2016 464,60
P/E ratio 2017 59,90
EV / Sales 2016 14,5x
EV / Sales 2017 10,1x
Capitalization 15 224 M
More Financials
Chart INCYTE CORPORATION
Duration : Period :
Incyte Corporation Technical Analysis Chart | INCY | US45337C1027 | 4-Traders
Full-screen chart
Technical analysis trends INCYTE CORPORATION
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 98,7 $
Spread / Average Target 22%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Hervé Hoppenot Chairman, President & Chief Executive Officer
David W. Gryska Chief Financial Officer & Executive Vice President
Reid M. Huber Chief Scientific Officer & Executive VP
Steven H. Stein Chief Medical Officer & Senior Vice President
Paul Alan Brooke Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
INCYTE CORPORATION-25.22%15 224
CELLTRION, INC.--.--%11 086
LONZA GROUP AG14.41%10 067
QUINTILES TRANSNATIONA..12.58%9 140
ALKERMES PLC-44.86%6 662
QIAGEN NV-4.12%6 407
More Results